Hypomethylation of 111 Probes Predicts Poor Prognosis for Glioblastoma

Glioblastoma is a complicated brain tumor with heterogeneous outcome. Identification of effective biomarkers is an urgent need for the treatment decision-making and precise evaluation of prognosis. Based on a relatively large dataset of genome-wide methylation (138 patients), a joint-score of 111 me...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in neuroscience Vol. 13; p. 1137
Main Authors Chen, Qi, Zhao, Min, Yin, Chengliang, Feng, Shiyu, Hu, Jian, Zhang, Qiang, Ma, Xiaodong, Xue, Wanguo, Shi, Jinlong
Format Journal Article
LanguageEnglish
Published Lausanne Frontiers Research Foundation 25.10.2019
Frontiers Media S.A
Subjects
biomarker
Biomarkers
Brain cancer
Brain tumors
Decision making
DNA methylation
DNA probes
Genetic analysis
Genomes
Glioblastoma
joint-score
methylation
Mutation
Neuroscience
Prognosis
prognostic evaluation
Risk factors
Beijing China
China
Online AccessGet full text

Cover

More Information
Summary:Glioblastoma is a complicated brain tumor with heterogeneous outcome. Identification of effective biomarkers is an urgent need for the treatment decision-making and precise evaluation of prognosis. Based on a relatively large dataset of genome-wide methylation (138 patients), a joint-score of 111 methyl-probes was found to be of statistical significance for prognostic evaluation. Low joint-score were significantly associated with adverse outcomes (OS: P < 0.001). Multivariable analyses adjusted for known risk factors confirmed the low joint-score of 111 methyl-probes as a high risk factor. The prognostic value of joint-score was further validated in another dataset of glioblastoma patients (OS: P = 0.006). Additionally, variance analysis revealed that aberrant genetic and epigenetic alterations were significantly associated with the joint-score of those methyl-probes. In conclusion, our results supported the joint-score of 111 methyl-probes as a potential prognosticator for the precision treatment of glioblastoma.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Edited by: Khyobeni Mozhui, The University of Tennessee Health Science Center (UTHSC), United States
Reviewed by: David G. Ashbrook, The University of Tennessee Health Science Center (UTHSC), United States; Apiwat Mutirangura, Chulalongkorn University, Thailand
This article was submitted to Neurogenomics, a section of the journal Frontiers in Neuroscience
ISSN:1662-453X
1662-4548
1662-453X
DOI:10.3389/fnins.2019.01137